Shikonin (Naphthoquinone)

Shikonin is a naphthoquinone compound extracted from Lithospermum erythrorhizon root that demonstrates anti-cancer properties through ROS-mediated apoptosis. This bioactive compound also exhibits anti-inflammatory effects by inhibiting key inflammatory markers like TNF-α and IL-1β.

Origin & History

Shikonin is a natural naphthoquinone compound primarily extracted from the roots of Lithospermum erythrorhizon (purple gromwell), a traditional medicinal herb. It is typically obtained through solvent-based extraction methods from the plant roots, yielding a characteristic red pigment with bioactive properties.

Historical & Cultural Context

Shikonin-rich extracts from Lithospermum erythrorhizon roots have been used in Traditional Chinese Medicine for centuries to promote wound healing and treat inflammation. Historical applications include topical use for burns and sores, with traditional antitumor activity noted in modern reviews.

Health Benefits

• May induce cancer cell death through ROS-dependent apoptosis in leukemia and solid tumors (preliminary evidence from in vitro and animal studies only)
• Potentially reduces inflammation markers including IL-1β, TNF-α, and COX-2 in osteoarthritis models (based on single rat study, n=10)
• May inhibit cancer cell migration and invasion by suppressing TRAP1 and AKT/mTOR signaling (in vitro evidence only)
• Shows promise for reducing cartilage degradation and chondrocyte apoptosis via PI3K/Akt pathway modulation (preclinical rat model)
• Demonstrates multi-target anticancer effects across various cancer cell lines including TNBC and esophageal cancer (cell culture studies only)

How It Works

Shikonin induces cancer cell death by generating reactive oxygen species (ROS) that trigger mitochondrial-mediated apoptosis pathways. The compound suppresses inflammatory responses by inhibiting nuclear factor-kappa B (NF-κB) signaling and reducing production of pro-inflammatory cytokines including TNF-α, IL-1β, and cyclooxygenase-2 (COX-2). Shikonin also demonstrates antimicrobial activity by disrupting bacterial cell membrane integrity.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted with shikonin. Evidence is limited to preclinical studies including in vitro cancer cell lines (PMC10135058, PMC8605926) and a single rat osteoarthritis model (PMC5038895) using 10 mg/kg/day intraperitoneally.

Clinical Summary

Evidence for shikonin comes primarily from in vitro cell culture studies and animal models, with no human clinical trials currently available. One rat study (n=10) showed reduced osteoarthritis inflammation markers, but this represents extremely limited evidence. Multiple laboratory studies demonstrate anti-cancer effects against leukemia and solid tumor cell lines, but translation to human efficacy remains unproven. The current evidence base is insufficient to establish clinical effectiveness or appropriate dosing protocols.

Nutritional Profile

Shikonin is a pure bioactive naphthoquinone compound, not a food ingredient, and therefore has no conventional nutritional profile in terms of macronutrients, vitamins, minerals, or fiber. It is a naturally occurring red pigment and secondary metabolite isolated primarily from the roots of Lithospermum erythrorhizon (purple gromwell) and related Boraginaceae family plants. Key compositional data: Shikonin is a hydroxynaphthoquinone with molecular formula C16H16O5 and molecular weight 288.3 g/mol; it exists as the levorotatory enantiomer (the dextrorotatory form is alkannin). Typical extraction yields from dried Lithospermum root range from 0.5–2.0% by dry weight. Bioactive compound concentration in standardized extracts is generally reported at ≥98% purity in research-grade isolates. It contains no protein, carbohydrates, dietary fiber, or conventional micronutrients. Bioavailability notes: Shikonin demonstrates poor aqueous solubility (lipophilic compound, logP approximately 3.0–3.5), which significantly limits oral bioavailability; nanoparticle formulations and lipid-based delivery systems have been studied to enhance absorption. Plasma half-life in animal models is reported as relatively short (approximately 1–3 hours), necessitating optimized delivery. It is metabolized hepatically and shows high protein binding in plasma. No established dietary reference intake or safe supplemental dose exists for humans.

Preparation & Dosage

No human dosage data available. Animal studies used 10 mg/kg/day intraperitoneally in rats for 4 days. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, Green tea extract, Resveratrol, Quercetin, Omega-3 fatty acids

Safety & Interactions

Safety data for shikonin in humans is extremely limited due to lack of clinical studies. Traditional use suggests potential skin irritation when applied topically, as shikonin is naturally found in plants used for wound healing. No documented drug interactions exist, but theoretical concerns include potential interactions with chemotherapy drugs due to its anti-cancer mechanisms. Pregnancy and breastfeeding safety is unknown, and use should be avoided during these periods.